The inability to significantly upregulate mevalonate pathway genes in response to the inhibition of HMGCR has also been reported in statin-sensitive multiple myeloma cells [11], indicating that this feature may be common across many tumor types and further suggests that our “cholesterol biosynthesis signature” may serve as a useful biomarker for statin sensitivity in not only breast cancer but other cancer types. Here, HMGCR is linked to cancer.